Appellant Roman Sterlin (“Plaintiff’) brought this securities fraud class action suit against Biomune Systems, Inc. (“Biomune”), David Derrick, Aaron Gold, Charles J. Quantz, Jack Solomon, Genesis Investment Corporation (“Genesis”), and the Institute for Social and Scientific Development (“Institute”) (collectively, “Defendants”). The district court dismissed the action, concluding that Plaintiffs claims were barred by the statute of limitations. From this dismissal, Plaintiff appeals. This court reverses and remands.
I. BACKGROUND
Biomune is a biotech company which, during the relevant time period, was developing a protein called Immuno-C to be used in enhancing human immune systems. David Derrick was Biomune’s President, CEO, Chairman of the Board, and main spokesperson. Aaron Gold and Charles Quantz were directors of Biomune. Jack Solomon founded Biomune, the Institute, and Genesis, and was a member of Biomune’s Business Advisory Board. Genesis manages Genesis Trust, whose beneficiaries are Solomon’s family members. Genesis Trust was at one time Biomune’s largest shareholder. Both Derrick and Gold were directors of Genesis. The Institute, a Utah corporation, was also a shareholder of Biomune. Gold served as a director of the Institute.
Plaintiff asserts this “action arises from a fraud of massive proportions,” generally consisting of a “scheme to obtain Biomune’s listing on NASDAQ, manipulate Biomune’s finances and inflate the price of Biomune stock in order to dump thousands of Biomune shares on the market and earn million[s] of dollars in profits.” Plaintiffs specific allegations in the Amended Complaint fall into two general categories: those concerning Biom-une’s NASDAQ listing and those concerning Biomune’s alleged misrepresentations regarding the efficacy of Immuno-C. 1
*1193 NASDAQ Listing. Plaintiff alleges that Biomune faced two obstacles in its attempt to obtain a NASDAQ listing. First, Biomune had to convince the Securities and Exchange Commission (“SEC”) that Solomon, who was subject to a consent decree for previous securities violations, did not maintain control over the company. Second, Biomune had to sufficiently increase its capital and surplus so that it could qualify for listing.
On March 7, 1994, NASDAQ notified Biomune that it was deferring consideration of its application pending a review by the NASDAQ Listing Qualifications Committee. NASDAQ was concerned with disciplinary actions taken against “a principal shareholder,” which Plaintiff alleges was Solomon. According to Plaintiff, Derrick drafted numerous affidavits, executed by himself and Gold, falsely attesting that Solomon did not maintain a control relationship with Biomune.
With respect to the manipulation of Biom-une’s capital and surplus, Plaintiff alleges that a “fraud network,” consisting of relatives and friends of Solomon and Derrick, effectuated a “cleanup” of Biomune’s balance sheet. Plaintiff alleges this plan took place in three parts during mid to late 1993. The first part involved an illegal Regulation S 2 offering of securities to increase Biomune’s capital and surplus. The second part of the plan consisted of Biomune’s purchase of Fur-tek Technologies from Brian Furtek, a longtime friend of Derrick, at an inflated price in an attempt to increase Biomune’s asset base. The third and final part was intended to eliminate Biomune’s long-term debt by entering into a phony settlement agreement with Genesis Trust. Plaintiff alleges that all of these transactions were entered into for the purpose of manipulating Biomune’s finances so that Biomune could obtain a NASDAQ listing. Plaintiff further alleges that during 1993 and 1994, Defendants made false and misleading statements regarding the financial stability and commercial success of Biomune.
Immuno-C Misrepresentations. Plaintiff alleges that in late 1993, Biomune retained Dr. Stephen Upton from the University of Kansas to perform Immuno-C testing on mice (the’ “Upton Study”). Plaintiff further alleges that Dr. Upton’s work was preliminary and contained a number of biases. Although several tests were unsuccessful, in one preliminary test Dr. Upton found that Immuno-C seemed to reduce the parasite level in mice, indicating that Immuno-C may be effective in the treatment of intestinal disorders. Plaintiff alleges that beginning with a press release on March 21, ‘ 1994, Defendants “launched their series of false and misleading announcements about the efficacy of Immuno-C based upon Dr. Upton’s results.” 3
Plaintiff further alleges that in late June or early July 1994, Defendants retained Dr. Mark Healey to perform additional testing of Immuno-C on mice. Dr. Healey completed his testing, which included both in vitro and in vivo tests, in early September 1994. The in vivo tests indicated that Immuno-C “did not demonstrate therapeutic efficacy,” though Dr. Healey suggested that further in vivo tests be performed. Dr. Healey’s in vitro tests, however, confirmed that Immu-no-C may be effective, though once again he recommended that further, testing be done.
Despite Dr. Healey’s recommendations, Defendants decided not to proceed with additional in vivo testing nor did they immediately disclose the results of the in vivo studies. Instead, Plaintiff alleges, Defendants disseminated several press releases emphasizing and exaggerating the importance of Dr. Upton’s preliminary study results and Dr. Hea-ley’s in vitro test results. Plaintiff further alleges that as a consequence of Defendants’ *1194 misleading statements, Biomune’s stock consistently traded at over $12.00 per share (pre-split).
On January 18, 1995, Biomune filed its Form 10-KSB for the fiscal year ending September 30, 1994. In the Form 10-K, Biomune disclosed the results of the Healey in vivo study. Plaintiff alleges that as a result of this disclosure, Biomune’s stock fell to $7.50 per share (pre-split) and has never recovered.
On October 12, 1995, Plaintiff brought this class action Complaint 4 on behalf of two classes: all persons who purchased Biomune common stock during the period September 15, 1993 through January 12, 1995 (“fraud class”); and all persons who purchased Biomune common stock contemporaneously with the sales of Biomune stock by Defendants Derrick, Genesis, and the Institute (“insider trading class”). In Count I, against all defendants, Plaintiff alleges a violation of § 10(b) of the Securities Exchange Act of 1934 (“1934 Act”) and Rule 10b-5 promulgated thereunder. In Count II, against Derrick, Gold, Quantz, and Solomon, Plaintiff alleges that each individual defendant is a control person of Biomune and is therefore liable under § 20(a) of the 1934 Act for the allegedly fraudulent conduct of Biomune. Count III, against Derrick, Genesis, and the Institute, alleges a violation of § 10(b) and Rule 10b-5 based on the defendants’ conduct in their positions as officers, advisors, and/or major stockholders. Finally, Count IV, also against Derrick, Genesis, and the Institute, alleges a violation of § 20A of the 1934 Act based on the defendants’ alleged insider trading.
After Plaintiff filed his Complaint, Defendants moved to dismiss, arguing,
inter alia,
the suit was barred by the applicable one-year statute of limitations. The district court agreed and dismissed the action.
See Sterlin v. Biomune Sys., Inc.,
II. DISCUSSION
This court reviews de novo the district court’s determination that Plaintiffs claims are barred by the statute of limitations.
See Industrial Constructors Corp. v. United States Bureau of Reclamation,
15
*1195
F.3d 963, 967 (10th Cir.1994). In conducting our review, we accept all well-pleaded allegations in the Complaint as true and construe them in the light most favorable to Plaintiff.
See Edwards v. International Union, United Plant Guard Workers of Am.,
In
Lampf, Pleva, Lipkind, Prupis & Petigrow.v. Gilbertson,
The Court rejected the plaintiffs’ argument that the applicable limitations period must be subject to the doctrine of equitable tolling.
8
See id.
at 363,
“where the party injured by the fraud remains in ignorance of it without any fault or want of diligence or care on his part, the bar of the statute does not begin to run until the fraud is discovered, though there be no special circumstances or efforts on the part of the party committing the fraud to conceal it from the knowledge of the other party.”
Id.
(quoting
Bailey v. Glover,
Shortly after the Supreme Court’s decision in
Lampf,
this court stated that the one-year discovery period set forth in
Lampf
commences when the plaintiff is put on “inquiry notice” of possible misrepresentations.
Anixter v. Home-Stake Prod. Co. [Anixter I],
A. Proceedings Below
The district court concluded that an article published in
Barron’s
nn August 1, 1994, put Plaintiff on inquiry notice, thus commencing the one-year statute of limitations period.
See Sterlin,
Plaintiff argues the district court erred in concluding the Barron’s article put him on inquiry notice of his claims. Among other things, Plaintiff argues that because he could not have discovered the results of the Healey study, and thus Defendants’ misrepresentations concerning the efficacy of Immuno-C, until Defendants publicly disclosed the Hea-ley study results in January 1995, he could not have been on notice of his claims as of August 1, 1994, the date the article was published. In other words, Plaintiff essentially argues that inquiry notice cannot exist until the facts underlying the cause of action are discoverable. Defendants, on the other hand, contend that the one-year statute of limitations period commences upon inquiry notice, without regard to when a plaintiff could reasonably have discovered the facts underlying his claims. Both arguments find support in circuit case law and, more specifically, in Tenth Circuit case law.
B. Tenth Circuit Cáse Law
On its face, the
Anixter I
opinion seems to support Defendants’ argument that the one-year limitations period begins to run when the plaintiff is placed on inquiry notice, regardless of whether an inquiry would have borne fruit. A closer reading of the opinion, however, coupled with subsequent opinions in the
Anixter
line of eases, suggests that inquiry notice alone may not be the determinative factor, at least when a reasonable investor could not reasonably have discovered the facts underlying the alleged fraud until some time after being placed on inquiry notice. Moreover,
Schwartz v. Celestial Seasonings, Inc.,
The plaintiffs in
Anixter I
had invested in various oil and gas production programs, known as Program Operating Corporations (“POCs”), with the expectation of receiving not only a return on their investment but also tax benefits through individual deductions of intangible drilling costs.
See Anixter I,
On appeal, the Anixter I court first held that the claims of the 1964-1969 classes were barred by the three-year statute of repose. See id. at 1436. The court then considered whether the one-year statute of limitations barred the claims of the 1970-1972 classes. See id. at 1440.
In determining when the one-year discovery period accrued for purposes of the 1970-1972 classes, the court stated that “[njotice is the key to our analysis, and merely ‘inquiry notice’ will do.”
10
Id.
at 1437. Accordingly, the one-year period “does not ‘commence only when a plaintiff has full knowledge of the existence of a claim. On the contrary, the one-year limitations period begins to run even when a plaintiff is placed on “inquiry notice” of possible misrepresentations.’ ”
Id.
(quoting
DeBruyne v. Equitable Life Assurance Soc’y of the United States,
The court determined the 1970 and 1971 plaintiff classes were put on inquiry notice in early 1971 and that their claims filed March 30, 1973, were therefore barred. See id. at 1440. In February 1971, the SEC filed a complaint against the defendants with respect to the 1970 POC, alleging violations of the registration and antifraud provisions of the federal securities laws. See id. at 1430-31. 'Shortly- thereafter, the Wall Street Journal published an article detailing the SEC’s allegations. See id. at 1431. The district court ultimately ordered the defendants to make a rescission offer to all participants in the 1970 POC. See id. On April 30, 1971, each participant in the 1970 POC was mailed a copy of the final judgment and a rescission offer prospectus. See id. Participants in the 1971 POC were also informed of the rescission offer by means of the 1971 prospectus. See id. at 1438 n. 36. In 1973, the IRS and SEC again undertook investigations of the defendants. See id. at 1431. In March 1973, the IRS informed the participants in the 1970 and 1971 POCs that it intended to disallow their claimed deductions for intangible drilling costs arising from the POCs based on its discovery that the defendants had not expended funds on drilling wells. See id. at 1438. In September 1973, the defendants filed a petition for reorganization under Chapter X of the Bankruptcy Act. See id. at 1431.
In holding that the claims of the 1970 and 1971 plaintiff classes were barred by the one-year limitations period, the Anixter I court rejected the plaintiffs’ arguments that they could not have discovered the fraud until March 1973 when the IRS informed them that the defendants had not expended funds on intangible drilling, but rather had converted the funds to their own uses. See id. at 1437. Instead, the court concluded the Wall Street Journal article, court order, and the rescission offer were sufficient to put plaintiffs on inquiry notice of their claims by April 30, 1971, thereby commencing the one-year limitations period. See id. at 1438, 1440. Because their complaint was not filed until March 30, 1973, almost two years later, the *1198 claims of the 1970 and 1971 plaintiff classes were barred. See id. at 1440.
The 1972 plaintiff class was added to the action by amendment on May 24, 1974. See id. The court concluded the filing of the original action on March 30, 1973 put the 1972 plaintiff class on inquiry notice, triggering the one-year statute of limitations period. See id. Consequently, the claims of the 1972 class were barred as well. See id.
The
Anixter I
court stated that the one-year statute of limitations period commenced when plaintiffs were put on inquiry notice, which the court described as sufficient facts to put a reasonable investor on notice of the possibility of fraud.
See id.
at 1437. Under a strict application of this standard, the one-year limitations period may begin to run before a reasonably diligent investor should have discovered the facts underlying the alleged fraudulent activity.
11
In its opinion partially granting the plaintiffs’ petition for rehearing, however, the court seemed to equate inquiry notice with the time when the plaintiffs reasonably should have discovered the facts underlying the alleged fraud.
See Anixter v. Home-Stake Prod. Co. [Anixter II],
After the
Anixter I
court dismissed the plaintiffs’ § 10(b) claims as time barred under the one-year/three-year limitations period, Congress passed legislation effectively overruling the retroactive application of the Supreme Court’s decision in
Lampf. See
FDIC Improvement Act of 1991, Pub.L. No. 102-242, § 476, 105 Stat. 2236, 2387 (codified as Securities Exchange Act of 1934 § 27A, 15 U.S.C. § 78aa-l). Under § 27A, courts were required to apply to
pre-Lampf
§ 10(b) claims the limitations period applicable in the appropriate jurisdiction prior to
Lampf. See id.
Following passage of § 27A, the
Anixter
plaintiffs sought reinstatement of their § 10(b) claims, arguing that under Oklahoma’s two-year limitations period, their claims were timely filed.
See Anixter v. Home-Stake Prod. Co. [Anixter III],
On petition for rehearing, however, the court determined that a remand to the district court was necessary to determine
*1199
whether the 1971 plaintiff class’s § 10(b) claims against the defendant law firm, which were added by amendment on May 24, 1974,
12
were timely filed in light of the court’s previous determination that the plaintiffs were on inquiry notice as of April 30, 1971. See
Anixter v. Home-Stake Prod. Co. [Anixter IV],
Thus, although the
Anixter I
opinion on its face states that the one-year limitations period commences upon inquiry notice, or the point when a reasonable investor is put on notice of the possibility of fraud, the subsequent
Anixter
opinions
13
recognize that when the plaintiffs could not have reasonably discovered the facts underlying the alleged fraud until some period after they were put on inquiry notice, the limitations period should not begin to run upon inquiry notice. This reading of the
Anixter
line of cases is supported by this court’s recent opinion in
Schwartz v. Celestial Seasonings, Inc.,
The plaintiff in Schwartz filed his class action complaint on May 5, 1995, alleging violations of the federal securities laws. See id. at 1255. The plaintiff alleged that during 1993 and 1994 the defendants misrepresented the circumstances surrounding a potential marketing agreement with another company. See id. at 1249. In May 1994, the defendant company announced it had entered into discussions to amend or terminate the agreement; after the announcement, the defendant company’s stock prices declined. See id. In considering whether the federal one-year statute of limitations barred the plaintiffs’ claims, this court rejected the defendants’ argument that company reports of limited success in 1993 and predictions of limited success in 1994 put the plaintiff on inquiry notice. See id. at 1255. Instead, the court held the action was timely filed because “[n]ot until the May 9, 1994 Form 10-Q [which first announced the defendant company was considering terminating the agreement] could plaintiff reasonably have discovered the violations.” Id.
C. Other Circuits’ Case Law
Cases from other circuits generally apply an inquiry notice standard 14 coupled with *1200 some form of reasonable diligence requirement in determining whether a plaintiffs securities claims are timely filed. The circuits are not consistent, however, in their determination of exactly when the one-year limitations period accrues. Moreover, this inconsistency exists not only among circuits but also within circuits. 15
Some courts have indicated the one-year limitations period begins to run once the plaintiff is put on inquiry notice, so long as the plaintiff could acquire actual knowledge of the facts underlying the fraudulent activity with the exercise of reasonable diligence.
16
For example, in
Great Rivers Cooperative v. Farmland Industries, Inc.,
Other courts have indicated the one-year limitations period commences when the plaintiff is placed on inquiry notice, unless the plaintiff can show the actual exercise of reasonable diligence to discover the fraud. If the plaintiff can show the exercise of such diligence, the limitations period begins to run when the plaintiff actually discovers the facts underlying the alleged fraud. If, however, the plaintiff cannot show such actual diligence, constructive knowledge of the fraud is imputed to the plaintiff as of the date of inquiry notice. For example, in
Dodds v. Cigna Securities, Inc.,
The Seventh Circuit, essentially merging the inquiry notice and reasonable diligence standards into one governing standard, has indicated that a plaintiff is not put on inquiry notice until the plaintiff reasonably should have discovered the fraud.
See Marks v. CDW Computer Ctrs., Inc.,
The First Circuit, based on the same rationale as the Seventh Circuit, has stated that while “ ‘storm warnings’ of the possibility of fraud trigger a plaintiffs duty to investigate in a reasonably diligent manner, ... his cause of action is deemed to accrue on the date when he
should have discovered
the alleged fraud.”
Maggio v. Gerard Freezer & Ice Co.,
D. Determination of Proper Standard
In this case the time between the date Plaintiff was allegedly placed on inquiry notice and the date Plaintiff claims he could reasonably have discovered the facts underlying the alleged fraud does affect the outcome. If this court accepts the district court’s determination that Plaintiff was on inquiry notice as of August 1, 1994, the date . the Barron’s article was published, but agrees with Plaintiff that a reasonable investor should not have discovered the facts underlying the fraud until January 1995, then the timeliness of Plaintiffs October 1995 filing hinges on the resolution of whether the limitations period begins to run when an investor is placed on inquiry notice or instead when the investor should reasonably have discovered the fraud.
This court concludes that inquiry notice, as defined by Anixter I, triggers an investor’s duty to exercise reasonable diligence and that the one-year statute of limitations period begins to run once the investor, in the exercise of reasonable diligence, should have discovered the facts underlying the alleged fraud. We reach this conclusion after a considered analysis of this circuit’s precedent, other circuits’ case law, and the policies underlying the securities laws.
As indicated above, language in the
Anixter
line of cases and in
Celestial Seasonings
supports our holding.
See supra
Part II.B. Further, consistent with our holding, a recent case from the Seventh Circuit has recognized that the one-year limitations period should not begin to run until a reasonable
*1202
investor should have discovered the facts underlying the alleged fraudulent activity.
19
See Marks,
Our holding further strikes a balance between two competing policies underlying the securities laws. While we recognize there is a strong federal interest in requiring plaintiffs to file suit soon after they are put on notice of their claims, the applicable statute of limitations should not precipitate groundless or premature suits by requiring plaintiffs to file suit before they can discover with the exercise of reasonable diligence the necessary facts to support their claims.
See Anixter I,
The purpose behind commencing the one-year limitations period upon inquiry notice is to discourage investors from adopting a wait- and-see approach.
See Tregenza v. Great Am. Communications Co.,
E. Application of Standard
1. Inquiry Notice
The district court determined that an article published in Baton’s on August 1, 1994, entitled “A Question of Immunity,” put Plaintiff on inquiry notice of his claims. In support of its conclusion, the district court quoted the following passages from the article:
“The story you’re about to read is true. And in its broad outlines, alas, oft-told. Not even the names have been changed. Maybe its retelling will protect a few innocents.
[The main body of the article is critical of Biomune’s research and claims regarding the effectiveness of Immuno-C.]
Concludes Hatch, who studied under one of Biomune’s founders at Brigham Young-University in the mid-Seventies, T don’t rule out the one in 100 chance that Biom- *1203 une actually has something. But if I were betting, I’d say the other 99% is going to rule.’
And that’s a bet, it turns out, based on considerably more than the scientific evidence. As Hatch knows — and anyone else who cares to take the trouble to research Biomune’s corporate history can discover — ever since its December 1981 founding as New Age Corp. — the company’s true raison d’etre hasn’t been shrimp farming in Ecuador or tomato cultivation in Egypt or immunity enhancers or any of the other ventures it’s run through. It’s been to sell shares — or, at the least, to use shares as currency to keep any number of its promoters’ ventures afloat.
And who are those promoters? The list is long and their connections colorful, but we will list only one. Biomune founder and consultant of long-standing is a Salt Lake City philanthropist, Jack D. Solomon. He owns no Biomune shares, according to the company’s SEC filings. But a byzantine array of entities in one way or another affiliated with Solomon own more than 35% of its stock. As it happens, way back when — in 1983 — the federal district court in Nevada permanently enjoined Solomon from violations of the registration, anti-fraud, stock ownership reporting and proxy solicitation provisions of the securities laws. Without admitting or denying the charges, Solomon consented to the filing of that injunction rather than fight SEC charges that, as president and chairman of Advanced Patent Technology Inc., he had illegally sold about 8.7 million shares of unregistered stock in purported private placements between 1975 and . late 1980 to raise money for APT’s purchase of a Las Vegas slot machine route business and other gáming-related enterprises. Over that span, APT’s shares climbed from pennies to just under $10 — and they subsequently went back to pennies, before being delisted from Nasdaq.
There’s a lesson there somewhere.”
Sterlin,
Plaintiff argues the district court erred in concluding the Barron’s article put him on inquiry notice. He characterizes the article as “consisting] primarily of sarcastic comments” 21 and asserts that nothing in the article even “raises the possibility” that Defendants made knowing misrepresentations about Immuno-C or knowingly manipulated the market for Biomune stock. With respect to the alleged misrepresentations about Im-muno-C, Plaintiff contends that any storm warnings raised by the article were premature, as the article was published only nine days after the Healey study commenced and over six weeks before the Healey results became available. Likewise, with respect to the fraud claim premised on Biomune’s NASDAQ listing, i.e., the illegal Regulation S offering, the acquisition of Furtek Technologies, and the settlement arrangement with Genesis, Plaintiff asserts that because the article did not even mention these transactions, “it would have been impossible” for the article to put him on notice. Finally, Plaintiff argues that two “dear shareholder” letters written by Derrick a few days after the Barron’s article was published sufficiently negated any suspicions raised by the article so that Plaintiff could not have been placed on inquiry notice.
Plaintiff misunderstands the nature of inquiry notice. As this court in
Anixter I
recognized, Plaintiff “ ‘need not ... have fully discovered the nature and extent of the fraud before [he was] on notice that something may have been amiss. Inquiry notice is triggered by evidence of the possibility of fraud, not full exposition of the scam itself.’ ”
“facts in the sense of indisputable proof or any proof at all, are different from facts calculated to excite inquiry which impose a duty of reasonable diligence and which, if pursued, would disclose the fraud. Facts in the latter, sense merely constitute objects of direct experience and, as such, may comprise rumors or vague charges if *1204 of sufficient substance to arouse suspicion.”
Cook v. Avien Inc.,
The 'district court correctly ruled that the
Barron’s
article, as a whole, created sufficient “storm warnings” to put a reasonable investor on notice of the possibility of fraudulent activity. Importantly, the
Barron’s
article questioned whether Biomune’s purpose was to create a viable product, Immuno-C, or whether it was in business simply to “sell shares.” The article pointed out that Solomon, who, according to Biomune’s SEC filings, owned no stock, actually owned more than 35% of Biomune’s stock through a “byzantine array of entities.” This statement related directly to Plaintiffs claim that Defendants fraudulently represented to the SEC that Solomon owned no Biomune stock in order to obtain Biomune’s NASDAQ listing. The article also stated that Solomon had been permanently enjoined in 1983 from violating various provisions of the securities laws. While insufficient by itself to establish inquiry notice, Sdomon’s prior history may be considered in determining whether Plaintiff was on inquiry notice.
Cf. Lenz v.
Asso
ciated Inns & Restaurants Co. of Am.,
Contrary to Plaintiffs assertions, the
Barron’s
article need not discuss each and every aspect of the alleged fraudulent activity to put him on notice of the need to inquire.
See In re Valence Tech., Inc. Sec. Litig.,
Once the storm clouds gathered, the “dear shareholder” letters from Derrick refuting the claims in the article could not dissipate them.
23
See id.
at 1438-39 & 1439 n. 37 (holding rescission offer and article put plaintiffs on inquiry notice even though defendant’s CEO issued assurances in response);
Great Rivers Coop.,
In sum, a reasonable investor would have investigated further after reading the Barron’s article. Contrary to Plaintiffs assertions, the “dear shareholder” letters did not relieve him of his duty to investigate. This court therefore concludes the article put Plaintiff on inquiry notice, triggering the duty to exercise reasonable diligence.
*1205 2. Reasonable Diligence
The district court did not address whether, in the exercise of reasonable diligence, Plaintiff should have discovered the facts underlying the alleged fraudulent activity prior to October 12, 1994, one year before he filed suit. Rather, the district court held the statute began to run on August 1, 1994, the date the Barron's article was published. We therefore remand to the district court to determine whether Plaintiffs Complaint was timely filed under the standard adopted herein. 24
III. CONCLUSION
Based on the foregoing discussion, this court REVERSES the district court’s dismissal of Plaintiffs Complaint and REMANDS for a determination of whether, under the standard announced herein, Plaintiffs Complaint was timely filed.
Notes
. Because this case was dismissed under Rule 12(b), we consider all facts in the Amended Complaint to be true and construe them in the light most favorable to Plaintiff.
See Edwards v. International Union, United Plant Guard Workers of Am.,
. Regulation S provides generally that offers or sales of securities that occur outside the United States are exempt from the registration requirements of § 5 of the Securities Act of 1933. See 17 C.F.R. §§ 230.901-.904.
. Plaintiff specifically alleges that Defendants disseminated false information concerning the Upton Study in the following disclosures during 1994: March 21 press release; April 12 package to investors; April 12 Dow Jones financial new-swire; May "dear shareholder” letters; May 23 press release; June 7 research report; June 15 press release; Form 8-KSB filed June 27; July 18 press release; August "dear shareholder” letters; August 11 press release; Form 10-QSB filed August 15; September 21 and 22 press releases; October 12 press release; and November 3 “dear shareholder” letter.
. Plaintiff filed his initial Complaint on October 12, 1995, and, after a limited merits discovery, filed his Amended Complaint on August 5, 1996. Unless otherwise noted, all references to Plaintiff's "Complaint” refer to his Amended Complaint.
. The district court dismissed all of Plaintiff's claims against all the defendants, concluding the claims were barred by the one-year limitations period applicable for § 10(b) claims.
See Sterlin v. Biomune Sys., Inc.,
Any person who violates any provision of this chapter or the rules or regulations thereunder by purchasing or selling a security while in possession of material, nonpuhlic information shall be liable in an action ... to any person who, contemporaneously with the purchase or sale of securities that is the subject of such violation, has purchased ... or sold ... securities of the same class.
15 U.S.C. § 78t-l(a). Section 20A further provides that "[n]o action may be brought under this section more than 5 years after the date of the last transaction that is the subject of the violation.”
Id.
§ 78t — 1(b)(4). Courts have interpreted § 20A as requiring the plaintiff to plead a predicate violation of the 1934 Act or its rules and regulations.
See, e.g., Jackson Nat’l Life Ins. Co.
v.
Merrill Lynch & Co.,
The district court apparently dismissed Plaintiff's § 20A claim because the predicate offenses under the 1934 Act, namely the § 10(b) claims, were dismissed as time barred. Plaintiff has not argued on appeal that his § 20A claim should survive even if the § 10(b) claims are ultimately dismissed. In light of our conclusion that this case must be remanded for the district court to determine whether Plaintiff’s § 10(b) claims were timely filed under the standard announced herein, we need not discuss whether his § 20A claim should survive the dismissal of his § 10(b) claims.
. Prior to the Supreme Court's decision in
Lampf,
numerous circuits, including this circuit, applied a state limitations period to § 10(b) claims.
See Lampf, Pleva, Lipkind, Prupis & Petigrow v. Gilbertson,
. The Court specifically cited § 9(e) and § 18(c) of the 1934 Act and § 13 of the 1933 Act.
See Lampf,
No action shall be maintained to enforce any liability created under section 77k or 77/ (2) of this title unless brought within one year after the discovery of the untrue statement or the omission, or after such discovery should have been made by the exercise of reasonable diligence. ... In no event shall any such action be brought to enforce a liability created under section 77k or 171 (1) of this title more than three years after the security was bona fide offered to the public, or under section 77/ (2) of this title more than three years after the sale.
Id.
§ 77m. The Court noted that to the extent the slight distinctions in terminology of the various periods might in the future prove significant, it selected the language of § 9(e) of the 1934 Act as the governing standard for an action under § 10(b).
See Lampf,
The one-year/three-yéar structure adopted by the
Lampf
Court thus incorporates a statute of limitations (one year from date of discovery) framed by a statute of repose (three years from date of violation).
See Anixter v. Home-Stake Prod. Co. [Anixter I],
.We note that the term "tolling” means " 'to suspend or stop temporarily,'" whereas the phrase "a cause of action accrues” refers to " 'when a suit may be maintained thereon.’ ”
Ebrahimi v. E.F. Hutton & Co.,
. A statute of repose "runs from a fixed date readily determinable by the defendant," thus serving the need for finality.
Caviness v. Derand Resources Corp.,
. The
Anixter I
court initially discussed whether the plaintiffs' § 11 and § 12 claims were timely filed under the one-year/three-year limitations period of § 13 of the 1933 Act.
See Anixter I,
. The
Anixter I
court did not focus on when the plaintiffs should have reasonably discovered the facts underlying the alleged fraud. In the background section of the opinion the court noted in passing that the
Anixter
jury had returned interrogatories on the question of equitable tolling and further noted that the district court held as a matter of law that the "plaintiffs did not discover nor should have discovered by the exercise of reasonable diligence the violations until September 1973, presumably when [the defendant company] filed for bankruptcy reorganization."
Anixter I,
.
See Anixter I,
. In determining when the federal one-year limitations period accrued in this case, this court may look to the
Anixter TV
court’s analysis of when the Oklahoma two-year statute of limitations period accrued. Although the
Anixter TV
court applied federal equitable tolling principles to determine when the state limitations period accrued, the Supreme Court noted in
Lampf
that these same principles are embodied in the federal one-year limitations period.
See Lampf,
.Not all circuits have addressed whether, under the Supreme Court’s analysis in
Lampf,
an inquiry notice standard, as opposed to an actual notice standard, should apply to § 10(b) claims. As discussed above, this circuit has determined that the one-year discovery period set forth in
Lampf
is subject to an inquiry notice standard.
*1200
See Anixter II,
.This inconsistency may be largely attributable to the fact that in many cases the court need not decide exactly when the one-year limitations period began to run, i.e., upon inquiry notice or only when the plaintiff reasonably should have discovered the facts underlying the alleged fraud.
See, e.g., Cooperativa de Ahorro y Credito Aguada v. Kidder, Peabody & Co.,
. Courts generally have not specified under this standard within what time frame the plaintiff must be able to discover the facts.
. The opinion in
Great Rivers
could also be read as holding that the one-year limitations period does not begin to run until the plaintiff reasonably should have discovered the facts underlying the alleged fraudulent activity. The court first noted that a reasonable investor would have been suspicious of possible misrepresentations upon reading an article in a newsletter about a class action suit against the defendant.
See Great Rivers Coop. v. Farmland Indus., Inc.,
. The
Marks
case dismissed the defendant’s reliance on
Whirlpool,
reasoning that the court in
Whirlpool
was “dispos[ing] of the plaintiff's equitable tolling argument rather than addressing an inquiry notice argument.”
Marks v. CDW Computer Ctrs., Inc.,
. We recognize that our phrasing of what constitutes inquiry notice is different from that of the Seventh Circuit. That circuit apparently holds that inquiry notice does not exist until the investor is able to discover the facts underlying the fraudulent activity.
See Marks,
. As discussed above, some courts have indicated that a plaintiff must actually exercise due diligence in order to "toll" the one-year limitations period.
See, e.g., Dodds v. Cigna Sec., Inc.,
. Defendants correctly note that many of these supposedly "sarcastic comments” made their way into Plaintiff's original Complaint.
. Although the determination of whether Plaintiff was on inquiry notice is judged by an objective standard, this court notes that Plaintiff's own buying pattern of Biomune stock supports our conclusion that the Barron's article was sufficient to put Plaintiff on inquiry notice. In the 11 months prior to the date the article was published, Plaintiff made 10 purchases of Biomune stock totaling approximately 13,000 shares. The day the article was published, August 1, 1994, Plaintiff purchased 333.33 shares, and after that date, he purchased only 33.33 shares.
. This court expresses no opinion on Plaintiff's argument that the "dear shareholder" letters affected his ability to discover the facts underlying the fraud.
. Defendants have advanced nine additional arguments for upholding the district court’s dismissal of Plaintiff’s Complaint. Because the district court concluded the Complaint was barred by the statute of limitations, it did not consider any of these arguments. This court declines to consider the arguments at this time and leaves them for the district court to address in the first instance.
